B. Braun Launches Cefazolin 3 g in DUPLEX® Container to Address Dosing Needs in Heavier Surgical Patients

B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, announced the launch of its new Cefazolin 3 g, the latest cefazolin dose addition to the DUPLEX^® Container portfolio.

Cefazolin is prescribed to prevent infections before, during or after surgery. B. Braun offers Cefazolin in 1 g, 2 g and now 3 g strength which is indicated for patients with body weight equal to or greater than 120 kg. The delivery of Cefazolin 3 g in the DUPLEX Container helps to ensure fast, simple and accurate administration with the added convenience of the right dose at the right time.

The DUPLEX Container is a ready-to-activate, two-compartment, flexible IV system that keeps pre-measured medication and diluent separate until ready to administer. Designed for easy stocking, DUPLEX Containers can be stored at room temperature with a minimum shelf life of 18 months and are compatible with automated medication dispensing systems.

"We are excited to add Cefazolin 3 g to our DUPLEX Container portfolio which allows us to address a previously unmet need for patients weighing 120 kg or more. DUPLEX Containers offer healthcare workers an easy-to-use solution that is activated at the bedside with no need for complicated reconstitution or messy thawing - saving time and labor for practitioners while reducing potential dosing errors," said Shawn Brinson, Director of Marketing, Injectable Drugs.

Cefazolin 3 g in DUPLEX Containers keeps premeasured medication and diluent separate until the healthcare worker is ready to administer at the bedside by simply folding, squeezing and shaking to reconstitute. A barcode referencing the final admixture, lot number and expiration date helps reduce medication errors, automate patient charting, track inventory and facilitate reimbursement tracking.